RET and non-small cell lung carcinoma: Another example is to combine the second-generation EGFR TKI osimertinib, which is active against the most important de novo mutation T790M that confers resistance to first-generation EGFR TKIs, with RET inhibition to overcome resistance to osimertinib due to acquired RET fusion in NSCLC (28).